JO3611B1 - سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم - Google Patents

سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم

Info

Publication number
JO3611B1
JO3611B1 JOP/2012/0223A JOP20120223A JO3611B1 JO 3611 B1 JO3611 B1 JO 3611B1 JO P20120223 A JOP20120223 A JO P20120223A JO 3611 B1 JO3611 B1 JO 3611B1
Authority
JO
Jordan
Prior art keywords
naphthyridinone
cyclopenta
pyrrole
dihydro
antibacterial
Prior art date
Application number
JOP/2012/0223A
Other languages
Arabic (ar)
English (en)
Inventor
David Francis Alain Lancois
Magali Madeleine Simone Motte
Jerôme Emile Georges Guillemont
Wendy Mia Albert Balemans
Anil Koul
Eric Pierre Alexandre Arnoult
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3611(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Application granted granted Critical
Publication of JO3611B1 publication Critical patent/JO3611B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JOP/2012/0223A 2011-08-10 2012-08-07 سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم JO3611B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10

Publications (1)

Publication Number Publication Date
JO3611B1 true JO3611B1 (ar) 2020-08-27

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0223A JO3611B1 (ar) 2011-08-10 2012-08-07 سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم

Country Status (24)

Country Link
US (7) US8906923B2 (enExample)
EP (1) EP2742045B1 (enExample)
JP (2) JP5921687B2 (enExample)
KR (1) KR101996862B1 (enExample)
CN (2) CN103874698B (enExample)
AR (1) AR087508A1 (enExample)
AU (1) AU2012293621B2 (enExample)
BR (1) BR112014003063B1 (enExample)
CA (1) CA2842518C (enExample)
CL (1) CL2014000289A1 (enExample)
DK (1) DK2742045T3 (enExample)
EA (1) EA201490438A1 (enExample)
ES (1) ES2721658T3 (enExample)
HU (1) HUE042978T2 (enExample)
IL (1) IL230549A (enExample)
JO (1) JO3611B1 (enExample)
MX (1) MX348128B (enExample)
PE (1) PE20141410A1 (enExample)
PH (1) PH12014500317A1 (enExample)
TR (1) TR201905537T4 (enExample)
TW (1) TWI568731B (enExample)
UA (1) UA111210C2 (enExample)
UY (1) UY34253A (enExample)
WO (1) WO2013021054A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6294822B2 (ja) 2011-08-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 抗菌性ピペリジニル置換3,4−ジヒドロ−1h−[1,8]−ナフチリジノン類
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CN104981466B (zh) * 2012-08-10 2019-06-14 爱尔兰詹森科学公司 抗细菌化合物
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
PL3880675T3 (pl) * 2018-11-12 2025-02-10 Debiopharm International Sa Związki antybiotykowe, sposoby ich wytwarzania, kompozycje farmaceutyczne zawierające te związki oraz ich zastosowanie
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
AU2022236404A1 (en) * 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
ATE332130T1 (de) 1999-10-08 2006-07-15 Affinium Pharm Inc Fab-i-hemmer
NZ517706A (en) 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
SI1828167T1 (sl) 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
WO2011061214A1 (en) 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Hivの治療のための組成物および方法
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
US9394295B2 (en) 2011-08-10 2016-07-19 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JP6294822B2 (ja) 2011-08-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 抗菌性ピペリジニル置換3,4−ジヒドロ−1h−[1,8]−ナフチリジノン類

Also Published As

Publication number Publication date
PH12014500317A1 (en) 2014-04-14
US10501463B2 (en) 2019-12-10
MX348128B (es) 2017-05-26
US20150080413A1 (en) 2015-03-19
US20180105525A1 (en) 2018-04-19
TR201905537T4 (tr) 2019-05-21
CN105461684A (zh) 2016-04-06
EP2742045B1 (en) 2019-01-23
KR20140072034A (ko) 2014-06-12
HK1199243A1 (zh) 2015-06-26
JP2014531404A (ja) 2014-11-27
IL230549A0 (en) 2014-03-31
BR112014003063A2 (pt) 2017-02-21
US9290493B2 (en) 2016-03-22
JP2016190843A (ja) 2016-11-10
AU2012293621B2 (en) 2016-07-21
WO2013021054A1 (en) 2013-02-14
US20170174683A1 (en) 2017-06-22
US20190084982A1 (en) 2019-03-21
UA111210C2 (uk) 2016-04-11
TWI568731B (zh) 2017-02-01
PE20141410A1 (es) 2014-10-13
NZ620212A (en) 2015-10-30
MX2014001600A (es) 2014-04-25
EP2742045A1 (en) 2014-06-18
CA2842518C (en) 2019-07-23
CA2842518A1 (en) 2013-02-14
US8906923B2 (en) 2014-12-09
HK1223352A1 (zh) 2017-07-28
US9617262B2 (en) 2017-04-11
KR101996862B1 (ko) 2019-07-05
TW201313714A (zh) 2013-04-01
US20140171451A1 (en) 2014-06-19
AU2012293621A1 (en) 2014-02-13
HUE042978T2 (hu) 2019-07-29
BR112014003063B1 (pt) 2020-11-17
CN105461684B (zh) 2018-09-25
ES2721658T3 (es) 2019-08-02
JP5921687B2 (ja) 2016-05-24
CN103874698A (zh) 2014-06-18
CL2014000289A1 (es) 2014-07-11
UY34253A (es) 2013-02-28
DK2742045T3 (en) 2019-04-23
US10526331B2 (en) 2020-01-07
US20190194194A1 (en) 2019-06-27
US10155759B2 (en) 2018-12-18
CN103874698B (zh) 2016-03-23
EA201490438A1 (ru) 2014-06-30
US9884864B2 (en) 2018-02-06
IL230549A (en) 2017-07-31
US20160194324A1 (en) 2016-07-07
AR087508A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
JO3611B1 (ar) سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
NZ708928A (en) Mannose derivatives for treating bacterial infections
WO2014007951A3 (en) Substituted tricyclic compounds as fgfr inhibitors
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
EA201490435A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные пиперидинилом
MX2011005934A (es) Compuestos organicos.
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
CU20110083A7 (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
WO2010063996A3 (en) Antibacterial compounds
MX2014001598A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
MX367309B (es) Nuevos compuestos antibacterianos.
MX2011008043A (es) Derivados de actagardina.
MX363480B (es) Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
PH12013500219A1 (en) Compounds with antibacterial activity against clostridium
MX357352B (es) Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico.
MX2013002398A (es) Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes.
WO2012018662A3 (en) Fused-imidazoyl compounds useful as antimicrobial agents
TN2011000248A1 (en) Organic compounds
UA113722C2 (uk) Фармацевтична композиція